Refile: US FDA approves Insmed's lung disease drug
12/08/2025 16:38
Corrects day to Tuesday from Wednesday Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed's INSM.O oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. (Reporting by Christy Santhosh and Unnamalai L in Bengaluru; Editing by Sriraj Kalluvila) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector